Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 30, 2008, Pages 10275-10276

  Freeman, Gordon J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 4; LIGAND; PD 1 LIGAND; PROTEIN KINASE C THETA; PROTEIN KINASE ZAP 70; PROTEIN PD 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; RECEPTOR PROTEIN; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DENDRITIC CELL; IMMUNE RESPONSE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

ANTIGENS, CD; ANTIGENS, CD28; APOPTOSIS REGULATORY PROTEINS; BINDING SITES; CELL MEMBRANE; CYTOPLASM; DIMERIZATION; GENE EXPRESSION REGULATION; HUMANS; IMMUNE SYSTEM; INFECTION; LIGANDS; MODELS, BIOLOGICAL; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 48749119366     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0805459105     Document Type: Note

References (16)

1. Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4:336-347.
2. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704.
3. Okazaki T, Honjo T (2007) PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol 19:813- 824.
4. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173:945-954.
5. Lin DY, et al. (2008) The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci USA 105:3011-3016.
6. Lazar-Molnar E, et al. (2008). Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci USA 105:10483-10488.
7. Barber DL, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687.
8. Brown JA, et al. (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170:1257-1266.
9. Dong H, Chen L (2003) B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 81:281-287.
10. Thompson RH, et al. (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66:3381-3385.
11. Ikemizu S, et al. (2000) Structure and dimerization of a soluble form of B7-1. Immunity 12:51-60.
12. Stamper CC, et al. (2001) Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 410:608-611.
13. Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC (2001) Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 410:604-608.
14. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ (2007) Programmed Death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27:111-122.
15. Pentcheva-Hoang T, Chen L, Pardoll DM, Allison JP (2007) Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci USA 104:17765-17770.
16. b. Immunity 9:519 -530.